Ahmed EL-Rashedy
This book outlines how generative AI is transforming pharmaceutical R&D from slow, trial-and-error screening to rapid, computationally driven molecular design. The Productivity Crisis: Generative AI combats the industry’s declining efficiency by actively designing purpose-built molecules rather than just evaluating existing chemical libraries. The AI Toolkit: The shift relies on advanced machine learning architectures-including VAEs, GANs, reinforcement learning, and 3D diffusion models-to generate structurally viable candidates. The Data Bottleneck: Because public databases are noisy and biased, successful AI pipelines require rigorous data auditing, transfer learning, and strict synthetic feasibility scoring to tether digital designs to wet-lab reality. The Modern Pipeline: While AI drastically accelerates target identification and de novo hit discovery, expert human chemists remain essential to filter out structural 'hallucinations' before physical synthesis begins. Future Frontiers: Generative design is paving the way for complex multi-target drugs (polypharmacology) and ultra-personalized therapies.
